B2M and neoplasm: To simulate the immune evasion mechanism of HLA-I downregulation in tumor cells in vitro, we first knocked out TAP1 and TAP2 simultaneously and knocked out B2M genes in several solid tumor cells (A375, A549 and 786-O) using CRISPR/Cas9 technology, respectively.